115 related articles for article (PubMed ID: 16892378)
1. Old molecules for new receptors: Trp(Nps) dipeptide derivatives as vanilloid TRPV1 channel blockers.
Bonache MA; García-Martínez C; García de Diego L; Carreño C; Pérez de Vega MJ; García-López MT; Ferrer-Montiel A; González-Muñiz R
ChemMedChem; 2006 Apr; 1(4):429-38. PubMed ID: 16892378
[TBL] [Abstract][Full Text] [Related]
2. Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides.
Norman MH; Zhu J; Fotsch C; Bo Y; Chen N; Chakrabarti P; Doherty EM; Gavva NR; Nishimura N; Nixey T; Ognyanov VI; Rzasa RM; Stec M; Surapaneni S; Tamir R; Viswanadhan VN; Treanor JJ
J Med Chem; 2007 Jul; 50(15):3497-514. PubMed ID: 17585749
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of indole-based peptoids as potent noncompetitive antagonists of transient receptor potential vanilloid 1.
Quintanar-Audelo M; Fernández-Carvajal A; Van Den Nest W; Carreño C; Ferrer-Montiel A; Albericio F
J Med Chem; 2007 Nov; 50(24):6133-43. PubMed ID: 17985859
[TBL] [Abstract][Full Text] [Related]
4. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
Surowy CS; Neelands TR; Bianchi BR; McGaraughty S; El Kouhen R; Han P; Chu KL; McDonald HA; Vos M; Niforatos W; Bayburt EK; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
J Pharmacol Exp Ther; 2008 Sep; 326(3):879-88. PubMed ID: 18515644
[TBL] [Abstract][Full Text] [Related]
5. Triazine-based vanilloid 1 receptor open channel blockers: design, synthesis, evaluation, and SAR analysis.
Vidal-Mosquera M; Fernández-Carvajal A; Moure A; Valente P; Planells-Cases R; González-Ros JM; Bujons J; Ferrer-Montiel A; Messeguer A
J Med Chem; 2011 Nov; 54(21):7441-52. PubMed ID: 21950613
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists.
Tamayo N; Liao H; Stec MM; Wang X; Chakrabarti P; Retz D; Doherty EM; Surapaneni S; Tamir R; Bannon AW; Gavva NR; Norman MH
J Med Chem; 2008 May; 51(9):2744-57. PubMed ID: 18386885
[TBL] [Abstract][Full Text] [Related]
7. Capsaicin receptor: TRPV1 a promiscuous TRP channel.
Pingle SC; Matta JA; Ahern GP
Handb Exp Pharmacol; 2007; (179):155-71. PubMed ID: 17217056
[TBL] [Abstract][Full Text] [Related]
8. Brain TRPV1: a depressing TR(i)P down memory lane?
Di Marzo V; Gobbi G; Szallasi A
Trends Pharmacol Sci; 2008 Dec; 29(12):594-600. PubMed ID: 18947889
[TBL] [Abstract][Full Text] [Related]
9. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
Honore P; Chandran P; Hernandez G; Gauvin DM; Mikusa JP; Zhong C; Joshi SK; Ghilardi JR; Sevcik MA; Fryer RM; Segreti JA; Banfor PN; Marsh K; Neelands T; Bayburt E; Daanen JF; Gomtsyan A; Lee CH; Kort ME; Reilly RM; Surowy CS; Kym PR; Mantyh PW; Sullivan JP; Jarvis MF; Faltynek CR
Pain; 2009 Mar; 142(1-2):27-35. PubMed ID: 19135797
[TBL] [Abstract][Full Text] [Related]
10. TRPV1 modulators: structure-activity relationships using a rational combinatorial approach.
Zaccaro L; García-López MT; González-Muñiz R; García-Martínez C; Ferrer-Montiel A; Albericio F; Royo M
Bioorg Med Chem Lett; 2011 Jun; 21(12):3541-5. PubMed ID: 21612926
[TBL] [Abstract][Full Text] [Related]
11. Solid-phase synthesis of new Trp(Nps)-containing dipeptide derivatives as TRPV1 channel blockers.
Pérez de Vega MJ; García-López MT; Zaccaro L; Royo M; Albericio F; Fernández-Carvajal A; Ferrer-Montiel A; González-Muñiz R
Molecules; 2010 Jul; 15(7):4924-33. PubMed ID: 20657400
[TBL] [Abstract][Full Text] [Related]
12. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.
Ognyanov VI; Balan C; Bannon AW; Bo Y; Dominguez C; Fotsch C; Gore VK; Klionsky L; Ma VV; Qian YX; Tamir R; Wang X; Xi N; Xu S; Zhu D; Gavva NR; Treanor JJ; Norman MH
J Med Chem; 2006 Jun; 49(12):3719-42. PubMed ID: 16759115
[TBL] [Abstract][Full Text] [Related]
13. TRPV1: a therapeutic target for novel analgesic drugs?
Szallasi A; Cruz F; Geppetti P
Trends Mol Med; 2006 Nov; 12(11):545-54. PubMed ID: 16996800
[TBL] [Abstract][Full Text] [Related]
14. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
[TBL] [Abstract][Full Text] [Related]
15. Analgesic dipeptide derivatives. II. Synthetic dipeptides containing a C-terminal 2-(2-nitrophenylsulfenyl) tryptophan residue.
García-López MT; González-Muñiz R; Herranz R; Molinero MT; Del Rio J
Int J Pept Protein Res; 1987 May; 29(5):613-20. PubMed ID: 3610476
[TBL] [Abstract][Full Text] [Related]
16. Membrane-tethered peptides patterned after the TRP domain (TRPducins) selectively inhibit TRPV1 channel activity.
Valente P; Fernández-Carvajal A; Camprubí-Robles M; Gomis A; Quirce S; Viana F; Fernández-Ballester G; González-Ros JM; Belmonte C; Planells-Cases R; Ferrer-Montiel A
FASEB J; 2011 May; 25(5):1628-40. PubMed ID: 21307333
[TBL] [Abstract][Full Text] [Related]
17. Answering the burning question of how transient receptor potential vanilloid-1 channel antagonists cause unwanted hyperthermia.
Ayoub SS; Hunter JC; Simmons DL
Pharmacol Rev; 2009 Sep; 61(3):225-7. PubMed ID: 19805475
[TBL] [Abstract][Full Text] [Related]
18. Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.
Gomtsyan A; Bayburt EK; Schmidt RG; Surowy CS; Honore P; Marsh KC; Hannick SM; McDonald HA; Wetter JM; Sullivan JP; Jarvis MF; Faltynek CR; Lee CH
J Med Chem; 2008 Feb; 51(3):392-5. PubMed ID: 18183945
[TBL] [Abstract][Full Text] [Related]
19. Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamides.
Doherty EM; Fotsch C; Bo Y; Chakrabarti PP; Chen N; Gavva N; Han N; Kelly MG; Kincaid J; Klionsky L; Liu Q; Ognyanov VI; Tamir R; Wang X; Zhu J; Norman MH; Treanor JJ
J Med Chem; 2005 Jan; 48(1):71-90. PubMed ID: 15634002
[TBL] [Abstract][Full Text] [Related]
20. [3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand for the human transient receptor potential vanilloid-1 (TRPV1) receptor.
Bianchi BR; El Kouhen R; Neelands TR; Lee CH; Gomtsyan A; Raja SN; Vaidyanathan SN; Surber B; McDonald HA; Surowy CS; Faltynek CR; Moreland RB; Jarvis MF; Puttfarcken PS
J Pharmacol Exp Ther; 2007 Oct; 323(1):285-93. PubMed ID: 17660385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
